Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron + solifenacin vs monotherapy in overactive bladder (wet OAB)
CTR20140097Phase 3Active
- Sponsor
- Astellas Pharma
- Start
- Jun 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mirabegron, solifenacin in overactive bladder (OAB), sponsored by Astellas Pharma. Started Jun 2014; status: active.
02
Drugs
mirabegronsolifenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on CTR20140097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140097.